← All trials
NCT04446299
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 13, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- Apr 30, 2021
- First posted
- Jun 24, 2020
- Last posted
- Jan 5, 2021
- Enrollment
- 520
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Braintree LaboratoriesLead sponsor
- Sebela PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.